Takamasa Ohki

Takamasa Ohki

Auto-generated profile, based on publicly available information

Takamasa Ohki

Department of Gastroenterology, Mitsui Memorial Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

15 September 2023 in Journal of Hepatology
Verified
Journal Article
Closed access
TMTatsuya Minami
Tatsuya Minami
MSMasaya Sato
Masaya Sato
HTHidenori Toyoda
Hidenori Toyoda
SYSatoshi Yasuda
Satoshi Yasuda
TYTomoharu Yamada
Tomoharu Yamada
RTRyosuke Tateishi
Ryosuke Tateishi

11 February 2020 in Drugs - Real World Outcomes
Verified
Journal Article
Open access
PDF file
TOTakamasa Ohki
Takamasa Ohki
KSKoki Sato
Koki Sato
MKMayuko Kondo
Mayuko Kondo
EGEriko Goto
Eriko Goto
TSTakahisa Sato
Takahisa Sato
SOShuntaro Obi
Shuntaro Obi
Background and Objective Experience of the use of lenvatinib (LEN) in the clinical setting remains limited. We conducted this study to elucidate the factors associated with progression-free survival (PFS) in patients with advanced HCC treated with LEN. Methods In this multicenter retrospective study, we analyzed data on patient characteristics, treatment outcomes, and adverse events (AEs) for 77 patients with advanced hepatocellular carcinoma (HCC). We also analyzed PFS and factors that influence PFS. Results The response rate to LEN was 29.9% and the disease control rate was 77.9%. Patients who achieved relative dose intensities of more than 70% had better outcomes (response rate 45.2% vs. 11.4%, P < 0.01). Appetite loss, fatigue, diarrhea, hypertension, and thyroid dysfunction were the most frequent AEs. Twenty-three patients (29.9%) had grade 3 or 4 AEs. Fifty-two patients (67.5%) required a dose reduction and 47 (61.0%) stopped taking the drug due to AEs. The PFS rates at 3, 6, and 12 months were 81.2%, 49.8%, and 34.8%, respectively. The median PFS was 5.6 months. Multivariate analysis showed that thyroid dysfunction of grade ≥ 2 (hazard ratio [HR] 4.57, 95% confidence interval [CI] 2.05–10.2, P < 0.01), appetite loss (HR 3.58, 95% CI 1.72–7.52, P < 0.01), and tumor diameter ≥ 40 mm (HR: 2.27, 95% CI 1.17–4.40, P = 0.015) were independent factors associated with poor PFS. On the other hand, Child–Pugh class 5A (HR 0.41, 95% CI 0.19–0.90, P = 0.027) and complete or partial response (HR 0.40, 95% CI 0.17–0.95, P = 0.039) were independent factors associated with better PFS. Conclusions Thyroid dysfunction and appetite loss after the administration of LEN were independent factors associated with shorter PFS, so these AEs should be carefully managed after administering LEN.

15 July 2021 in Gut and Liver
Verified
Journal Article
Open access
PDF file
YKYuki Karasawa
Yuki Karasawa
JKJun Kato
Jun Kato
SKSatoshi Kawamura
Satoshi Kawamura
KKKentaro Kojima
Kentaro Kojima
TOTakamasa Ohki
Takamasa Ohki
NTNobuo Toda
Nobuo Toda
Yuki Karasawa, Jun Kato, Satoshi Kawamura, Kentaro Kojima, Takamasa Ohki, Michiharu Seki, Kazumi Tagawa, and Nobuo Toda. Gut and Liver 2021;15:616-24. https://doi.org/10.5009/gnl20214

2 June 2019 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
CSChikako Shibata
Chikako Shibata
JKJun Kato
Jun Kato
NTNobuo Toda
Nobuo Toda
MIMakoto Imai
Makoto Imai
YFYukiyo Fukumura
Yukiyo Fukumura
KTKazumi Tagawa
Kazumi Tagawa
While dermatomyositis is often associated with malignancy, several autoimmune diseases like myositis can be caused by immune checkpoint inhibitors. Differentially diagnosing malignancy-associated dermatomyositis or myositis caused by immune checkpoint inhibitors is sometimes difficult, particularly when a patient with malignancy shows the symptoms of myositis after checkpoint inhibitor administration. We experienced such a case in which we had difficulties in diagnosing paraneoplastic dermatomyositis or drug-associated myositis. In this case, all of our team initially assumed that the diagnosis was myositis caused by immune checkpoint inhibitors. However, it turned out finally that the diagnosis was paraneoplastic dermatomyositis. Because the diagnosis was unexpected, we report here. We report the case of a 71-year-old Japanese man who developed clinical symptoms of myositis, such as muscle aches and weakness, after initiation of nivolumab therapy for his gastric cancer. He was initially diagnosed with nivolumab-induced myositis, because the myositis symptoms appeared after nivolumab administration, and nivolumab is known to trigger various drug-associated autoimmune diseases. However, according to his characteristic skin lesions, the type of muscle weakness, his serum marker profiles, electromyography of his deltoid muscle, and magnetic resonance imaging, he was finally diagnosed as having paraneoplastic dermatomyositis. Accordingly, treatment with intravenously administered corticosteroid pulse treatment, immunoglobulin injection, and tacrolimus was applied; his symptoms subsequently improved. However, to our regret, at day 142 after administration, he died due to rapid worsening of his gastric cancer. Differentially diagnosing paraneoplastic dermatomyositis or drug-associated myositis caused by immune checkpoint inhibitors is difficult in some cases. The differential diagnosis is crucial because it influences the decision regarding the appropriateness of the use of immunosuppressive treatment against the autoimmune diseases as well as the decision regarding the appropriateness of the continuous use of immune checkpoint inhibitors against the primary cancers. Because subclinical autoimmune disease may become overt after administering immune checkpoint inhibitors, non-apparent autoimmune diseases, which have already existed, should also be considered to avoid the delay of appropriate treatment, when symptoms of autoimmune diseases are recognized.

25 January 2011 in Hepatology International
Verified
Journal Article
Closed access
PDF file
TGTadashi Goto
Tadashi Goto
HYHaruhiko Yoshida
Haruhiko Yoshida
RTRyosuke Tateishi
Ryosuke Tateishi
KEKenichiro Enooku
Kenichiro Enooku
EGEriko Goto
Eriko Goto
MOMasao Omata
Masao Omata